Last: | $1.71 |
---|---|
Change Percent: | -2.21% |
Open: | $1.85 |
Close: | $1.71 |
High: | $1.85 |
Low: | $1.69 |
Volume: | 80,179 |
Last Trade Date Time: | 04/26/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$1.71 | $1.85 | $1.71 | $1.85 | $1.69 | 80,179 | 04-26-2024 |
$1.81 | $1.79 | $1.81 | $1.85 | $1.67 | 130,536 | 04-25-2024 |
$1.79 | $1.79 | $1.79 | $1.83 | $1.69 | 107,568 | 04-24-2024 |
$1.72 | $1.63 | $1.72 | $1.82 | $1.63 | 87,853 | 04-23-2024 |
$1.65 | $1.68 | $1.65 | $1.7146 | $1.58 | 55,767 | 04-22-2024 |
$1.61 | $1.72 | $1.61 | $1.794 | $1.6 | 103,321 | 04-19-2024 |
$1.73 | $1.76 | $1.73 | $1.84 | $1.71 | 73,529 | 04-18-2024 |
$1.79 | $1.83 | $1.79 | $1.89 | $1.65 | 92,978 | 04-17-2024 |
$1.85 | $1.77 | $1.85 | $1.85 | $1.71 | 57,222 | 04-16-2024 |
$1.77 | $1.89 | $1.77 | $1.9 | $1.72 | 86,012 | 04-15-2024 |
$1.85 | $1.92 | $1.85 | $1.99 | $1.85 | 39,197 | 04-12-2024 |
$1.95 | $1.96 | $1.95 | $1.98 | $1.9 | 53,831 | 04-11-2024 |
$1.86 | $1.92 | $1.86 | $1.9922 | $1.812 | 213,376 | 04-10-2024 |
$1.94 | $1.91 | $1.94 | $2.087 | $1.91 | 72,614 | 04-09-2024 |
$1.92 | $2.11 | $1.92 | $2.2 | $1.92 | 159,949 | 04-08-2024 |
$2.135 | $2.24 | $2.135 | $2.26 | $2.1 | 116,981 | 04-05-2024 |
$2.22 | $2.41 | $2.22 | $2.43 | $2.19 | 145,267 | 04-04-2024 |
$2.33 | $2.16 | $2.33 | $2.41 | $2.14 | 219,141 | 04-03-2024 |
$2.18 | $2.11 | $2.18 | $2.296 | $2.08 | 159,714 | 04-02-2024 |
$2.11 | $2.27 | $2.11 | $2.3252 | $2.01 | 404,015 | 04-01-2024 |
News, Short Squeeze, Breakout and More Instantly...
Equillium Inc. Company Name:
EQ Stock Symbol:
NASDAQ Market:
Positive EBITDA and quarterly revenue increased by 19% TORONTO, ON / ACCESSWIRE / April 15, 2024 / EQ Inc. (TSXV:EQ.V) ("EQ Works" or the "Company"), a leader in AI and data driven software and solutions, announced its financial results today for the fourth quarter and the year ended Decembe...
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that on April 1, 2024, the Compensation Committee of Equillium’s Board of Directors granted an inducement awa...
Topline data delivered to Ono Pharmaceutical, representing the first of two data sets that will trigger Ono’s option exercise decision for itolizumab Itolizumab continues to show clinically meaningful response in highly proteinuric subjects More than 80% of subjects achieve...